Business Description
Elevation Oncology Inc
NAICS : 541713
SIC : 2834
ISIN : US28623U1016
Description
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.76 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.55 | |||||
| Debt-to-EBITDA | -0.73 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.2 | |||||
| 3-Year EPS without NRI Growth Rate | -5.4 | |||||
| 3-Year FCF Growth Rate | -30.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.37 | |||||
| 9-Day RSI | 31.63 | |||||
| 14-Day RSI | 36.78 | |||||
| 6-1 Month Momentum % | 825.93 | |||||
| 12-1 Month Momentum % | 65.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.22 | |||||
| Quick Ratio | 21.22 | |||||
| Cash Ratio | 20.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23 | |||||
| Shareholder Yield % | -0.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -83.95 | |||||
| ROA % | -48.57 | |||||
| ROIC % | -1238.18 | |||||
| ROC (Joel Greenblatt) % | -18800.54 | |||||
| ROCE % | -49.24 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.81 | |||||
| Price-to-Tangible-Book | 2.81 | |||||
| EV-to-EBIT | -3 | |||||
| EV-to-EBITDA | -3 | |||||
| EV-to-FCF | -2.21 | |||||
| Price-to-Net-Current-Asset-Value | 2.85 | |||||
| Price-to-Net-Cash | 3.15 | |||||
| Earnings Yield (Greenblatt) % | -33.33 | |||||
| FCF Yield % | -31.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ELEV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elevation Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.47 | ||
| Beta | 0 | ||
| Volatility % | 435.68 | ||
| 14-Day RSI | 36.78 | ||
| 14-Day ATR ($) | 0.400537 | ||
| 20-Day SMA ($) | 4.45825 | ||
| 12-1 Month Momentum % | 65.02 | ||
| 52-Week Range ($) | 0.363 - 5.89 | ||
| Shares Outstanding (Mil) | 48.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elevation Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elevation Oncology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Elevation Oncology Inc Frequently Asked Questions
What is Elevation Oncology Inc(ELEV)'s stock price today?
The current price of ELEV is $3.62. The 52 week high of ELEV is $5.89 and 52 week low is $0.36.
When is next earnings date of Elevation Oncology Inc(ELEV)?
The next earnings date of Elevation Oncology Inc(ELEV) is 2024-05-15 Est..
Does Elevation Oncology Inc(ELEV) pay dividends? If so, how much?
Elevation Oncology Inc(ELEV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers